BRISBANE, Calif., June 14 /PRNewswire/ -- BiPar Sciences, Inc., a privately-held biopharmaceutical company focused on novel therapeutics for cancer, announced today it has secured a $5 million venture debt commitment from Lighthouse Capital Partners. The company plans to use the funding to accelerate and expand the clinical program for its lead compound, BSI-201, and move two additional compounds toward clinical development.
